菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Newsletter: September 2020

Latest Articles and Podcasts

Continuous Biomanufacturing Implementation – Using an Intensified and Integrated Bioprocess Platform Read More

Reducing Fill Risk in Drug Product Manufacture Utilizing New State-of-the-Art Systems and Platforms Read More

The Challenge of Staying Current with Regulatory Changes – How one company is providing a solution. Read More


Financial Results

 

WuXi Biologics Records Excellent Interim Results Read More


Facilities and Operations

 

WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States (Cranbury, NJ) Read More

 

WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in Worcester, MA Read More

 

WuXi Biologics Completed Acquisition of a Drug Product Manufacturing Facility in Germany Read More

 

WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection Read More

 

WuXi Biologics Successfully Completes PFS Filling at its Robotic Aseptic Filling Facility Read More

 


Resources

 

Fierce Pharma Virtual Series on COVID-19 Expert Panel Discussion Featuring Chris Chen Read More

 

Antibody Drug Conjugates (ADC) Drug Development and Manufacturing Trends, Challenges and Solutions Read More

 

New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties And Manufacturability  Read More


Partner News

 

WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform Read More

 

WuXi Biologics & Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19 Read More

 

WuXi Biologics Congratulates Immutep on Positive Interim data for IMP-321 Read More


Awards and Achievements

 

WuXi Biologics Awarded as “Most Honored Company” by Institutional Investor Read More

 

WuXi Biologics Sweeps 2020 CMO Leadership Awards in All Six Categories Read More

 

WuXi Biologics standardizes a remarkable 12 month “DNA to IND” timeline through its streamlined development platform Read More